Compare · KYNB vs NVO
KYNB vs NVO
Side-by-side comparison of Kyntra Bio Inc. (KYNB) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KYNB and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 6824.2x KYNB ($26.8M).
- Over the past year, KYNB is down 15.8% and NVO is down 45.7% - KYNB leads by 29.8 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 2 for KYNB).
- NVO has more recent analyst coverage (25 ratings vs 0 for KYNB).
- Company
- Kyntra Bio Inc.
- Novo Nordisk A/S
- Price
- $6.65-3.62%
- $41.01-4.51%
- Market cap
- $26.8M
- $183.15B
- 1M return
- -6.34%
- -10.44%
- 1Y return
- -15.82%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 2
- 8
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest KYNB
- Amendment: CEO Wettig Thane bought $19,852 worth of shares (2,800 units at $7.09), increasing direct ownership by 11% to 27,203 units (SEC Form 4)
- CEO Wettig Thane decreased direct ownership by 9% to 27,203 units (SEC Form 4)
- SEC Form 10-Q filed by Kyntra Bio Inc.
- Kyntra Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
- Kyntra Bio to Report First Quarter 2026 Financial Results
- SEC Form DEFA14A filed by Kyntra Bio Inc.
- SEC Form DEF 14A filed by Kyntra Bio Inc.
- Kyntra Bio Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care